Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin texture abnormal23.03.03.0680.000820%Not Available
End stage renal disease20.01.03.0190.001206%Not Available
Intracranial mass17.11.01.0170.000482%Not Available
Tongue discomfort07.14.02.0190.001760%Not Available
Biliary obstruction09.02.02.0050.000362%Not Available
Breast discolouration23.03.03.073; 21.05.05.0160.000940%Not Available
Colorectal adenoma16.05.02.009; 07.20.01.0190.000241%Not Available
Disease complication08.01.03.0870.003665%Not Available
Gait inability08.01.02.011; 17.02.05.0690.010898%Not Available
Hyperaesthesia teeth07.09.06.0050.000940%Not Available
Illness08.01.03.0910.052900%Not Available
Limb mass15.03.05.0190.000940%Not Available
Periorbital swelling10.01.05.025; 06.08.03.032; 23.04.01.0250.001230%Not Available
Physical deconditioning08.01.03.0960.000723%Not Available
Plasma cell myeloma in remission16.23.02.007; 01.14.02.0070.000820%Not Available
Product intolerance08.06.01.0450.000820%Not Available
Pulmonary amyloidosis22.01.02.034; 10.02.05.0100.000241%Not Available
Sensitive skin23.03.03.0970.003689%Not Available
Signet-ring cell carcinoma16.16.01.0230.000241%Not Available
Sinus pain22.12.03.0230.000530%
Skin cancer metastatic23.08.02.013; 16.03.02.0130.000241%Not Available
Superficial vein thrombosis24.01.02.0160.001133%Not Available
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.0180.001061%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.013189%Not Available
Vertebral column mass15.02.04.0480.000241%Not Available
The 16th Page    First    Pre   16    Total 16 Pages